LINC00158: A Potential Drug Target and Biomarker (G54072)

Target Name: LINC00158

NCBI ID: G54072

LINC00158

Other Name(s): C21orf42 | NCRNA00158 | long intergenic non-protein coding RNA 158 | Long intergenic non-protein coding RNA 158

LINC00158: A Potential Drug Target and Biomarker

LINC00158 is a long non-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a member of the LINC RNA family, which is known for its ability to regulate gene expression and play a role in various cellular processes. LINC00158 has been shown to be involved in a variety of physiological processes, including cell adhesion, migration, and invasion.

The search for drug targets and biomarkers is a crucial aspect of modern medicine. Drug development involves identifying small molecules that can interact with specific targets and lead to the inhibition of a particular protein or RNA. These drugs can then be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

LINC00158 as a Drug Target

LINC00158 has been shown to be a potential drug target by its ability to interact with the protein known as PDGF-BB. PDGF-BB is a protein that plays a role in cell proliferation and survival, and is often involved in the development and treatment of cancer. LINC00158 has been shown to regulate the expression of genes that are involved in the development and survival of cancer cells, including the PDGF signaling pathway.

In addition to its potential role in cancer, LINC00158 has also been shown to be involved in the development and progression of neurodegenerative diseases. neurodegenerative diseases are a group of disorders that are characterized by the progressive loss of brain cells and their corresponding functions. LINC00158 has been shown to be involved in the development and progression of neurodegenerative diseases by its ability to regulate the expression of genes involved in the development and maintenance of neural stem cells.

LINC00158 as a Biomarker

In addition to its potential role as a drug target, LINC00158 has also been shown to be a potential biomarker for a variety of diseases. For example, LINC00158 has been shown to be involved in the diagnosis of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This is based on its ability to be expressed in the brains of individuals with neurodegenerative diseases and its ability to interact with the proteins involved in the development and progression of these diseases.

In addition to its potential use as a drug target and biomarker, LINC00158 has also been shown to have a variety of other physiological functions. For example, it has been shown to play a role in cell adhesion and migration, and has been shown to be involved in the regulation of various cellular processes, including cell cycle progression and apoptosis.

Conclusion

In conclusion, LINC00158 is a potential drug target and biomarker that has been shown to be involved in a variety of physiological processes. Its potential drug target status and its ability to be used as a biomarker make it an attractive candidate for further research and development. Further studies are needed to fully understand the role of LINC00158 in various biological processes and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 158

The "LINC00158 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00158 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets